ImVisioN
healing AG, a biopharmaceutical company pioneering intralymphatic immunotherapy (ILIT™), today announced that it has obtained perfect Phase I clinical results for its lead product, IVN201 (Cat-MAT), an immunotherapeutic product for the head injuries & strokes: ukwww.royalbucks.co.uk
copyrights:cite this source roget's ii: the new lexicon



if (lexico_globals.googleafc.ads.content.length)
{
document.write(lexico_globals.googleafc.ads.contenttop);
document.write(lexico_globals.googleafc.ads.sponsoredlinks);
document.write(lexico_globals.googleafc.ads.content[2]);
document.write("") of cat dander allergy. The study was conducted from August 2008 to March 2009 in a total of 20 specialty with allergy to cat dander.

More: - Brought to my attention by